Non-Immunosuppressive, Non-TPO Receptor Agonist Therapy in Aplastic Anemia
Indian Journal of Hematology and Blood Transfusion · 2026-11 · 42 (6) · 2359-2363
DOI: 10.1007/s12288-026-02516-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Indian Journal of Hematology and Blood Transfusion, online erschienen am 03.09.2026. Verfasst von Tribikram Panda und 1 weiteren Autor:innen. Beteiligte Einrichtung: Hemato Oncology and BMT, BSSCCRI, Bhubaneswar, Odisha India. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
To understand the principles and rationale of supportive care in aplastic anemia. To review evidence-based strategies for transfusion support, infection prevention, and iron chelation. To recognize the role and limitations of vaccination, psychosocial support, and androgen therapy. To apply practical, context-specific supportive care approaches relevant to resource-constrained settings such as India. Aplastic anemia (AA) is a life-threatening bone marrow failure disorder characterized by pancytopenia and hypo cellular marrow. While hematopoietic stem cell transplantation (HSCT) and immunosuppressive therapy remain the definitive treatment options for severe immune-mediated AA, most patients require immediate supportive care to stabilize clinical status, prevent complications, and bridge to definitive therapy. Key supportive strategies include phenotype-matched restrictive transfusion support, management of thrombocytopenia-related bleeding, leukoreduction and selective irradiation of blood components, iron chelation in transfusion-dependent patients, comprehensive infection prevention and timely antimicrobial therapy, vaccination planning, and psychosocial support. The role of androgens continues in selected patients, particularly in non-severe disease or resource-limited settings. Evidence-based supportive care is crucial to improving survival, reducing morbidity, and maintaining quality of life, especially in the Indian context where resource constraints influence therapeutic decisions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hemato Oncology and BMT, BSSCCRI, Bhubaneswar, Odisha India.
- Clinical Hematology, BMT & Cellular Therapy, Utkal Hospital, Bhubaneswar, India.
Zitieren
APA
Panda, T., & Jena, R. K. (2026). Non-Immunosuppressive, Non-TPO Receptor Agonist Therapy in Aplastic Anemia. Indian Journal of Hematology and Blood Transfusion, 42(6), 2359-2363. https://doi.org/10.1007/s12288-026-02516-2
Vancouver
Panda T, Jena RK. Non-Immunosuppressive, Non-TPO Receptor Agonist Therapy in Aplastic Anemia. Indian Journal of Hematology and Blood Transfusion. 2026;42(6):2359-2363. doi:10.1007/s12288-026-02516-2
BibTeX
@article{Panda2026,
author = {Panda, Tribikram and Jena, Rabindra Kumar},
title = {Non-Immunosuppressive, Non-TPO Receptor Agonist Therapy in Aplastic Anemia},
journal = {Indian Journal of Hematology and Blood Transfusion},
year = {2026},
volume = {42},
number = {6},
pages = {2359--2363},
doi = {10.1007/s12288-026-02516-2}
}
EUVIMED